Genomic Health
PreludeDx DCIS Breast Cancer Test Helps Determine Radiation Therapy Benefits, Reduce Overtreatment
Premium
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
Exact Sciences Oncotype DX Identifies Postmenopausal Breast Cancer Patients Who Can Forgo Chemo
Premium
The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.
Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
OncotypeDX Score May Give Valuable Info on Breast Cancer Locoregional Recurrence
Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.
Jun 13, 2019
May 7, 2019
Genomic Health Q1 Revenues Up 17 Percent
Feb 22, 2019
Dec 14, 2018
Aug 3, 2018